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INTRODUCTION:  The  association  of  hepatic  sarcoidosis  with  hepatocellular  carcinoma  (HCC)  is  consider-
ably  rare.  Here  we report  a rare case  of  HCC  associated  with  sarcoidosis.
PRESENTATION  OF  CASE:  A 75-year-old  male  with  no history  of  alcohol  addiction  or viral  hepatitis  was
referred  to our  hospital  because  of an  abnormal  liver  mass.  Subsegmentectomy  of  the  liver was performed
for  the diagnosis  of  HCC. A  histopathological  examination  revealed  small  non-necrotizing  granulomas
with  a  tendency  to  coalesce  that  were  scattered  in  and  around  the  carcinoma.  No  features  of  cirrhosis,
steatohepatitis,  and  any  other  liver  diseases  were  observed.  Furthermore,  swelling  of  the  bilateral  lung
hilar  lymph  nodes  with  uptake  of 18F-ﬂuorodeoxyglucose  was  found  on  positron  emission  tomogra-
phy/computed  tomography  and  the  tuberculin  reaction  test  results  were  negative.  On  the  basis  of  these
ﬁndings,  the  ﬁnal  diagnosis  of  HCC  associated  with  sarcoidosis  was  conﬁrmed.
DISCUSSION:  By  reviewing  previous  cases,  we  found  only  ﬁve  cases  that described  patients  diagnosed  with
HCC  associated  with  sarcoidosis.  Of these,  four  patients  died within  two  years  after  diagnosis  because
of  ruptures  or  inoperable  huge  tumors.  In contrast,  radical  hepatectomy  was  performed  at  an  earlier
stage  of  disease  in  two  patients,  including  ours,  and  both  these  patients  have  remained  healthy  with  no
recurrences  or metastases  at the  latest  follow-up  visit.
CONCLUSION:  Periodic  checkups  of the liver  should  be conducted  for patients  with  systemic  sarcoidosis,
regardless  of the  presence  of liver  cirrhosis.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Sarcoidosis is a multisystem disorder characterized by the pres-
nce of noncaseating granulomas in affected tissues.1 The most
ommonly affected organs are the lungs and lymph nodes, followed
y the liver, although several other organs can also be involved,
ncluding the liver, skin, eyes, heart, and brain.
Previous reports have documented evident liver involvement in
pproximately 50–80% of cases by biopsy and approximately 70%
y autopsy.2–4 However, the diagnosis of hepatic sarcoidosis is dif-
cult because liver dysfunction is often mild and the condition is
linically silent in most cases.5,6 Furthermore, hepatic sarcoidosis
arely causes severe complications such as jaundice, liver failure,
irrhosis, and portal hypertension, and the symptoms of cirrho-
is or portal hypertension are reportedly present in ≤1% of the
ases.7 Granulomas may  lead to chronic intrahepatic cholestasis
ith the loss of interlobular bile ducts, and these conditions may
Abbreviations: HCC, hepatocellular carcinoma; CT, computed tomography; Gd-
OB-DTPA, gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid.
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sequentially lead to the development of periportal ﬁbrosis or
micronodular cirrhosis.8 In addition, the association of hepatic
sarcoidosis with hepatocellular carcinoma (HCC) is thought to be
considerably rare. Here we report a rare case of a 75-year-old male
who was  diagnosed with HCC associated with sarcoidosis and was
treated by subsegmentectomy of the liver and cholecystectomy.
2. Presentation of case
A 75-year-old male was  referred to our hospital for an abnormal
liver mass detected on ultrasonography during a periodic medical
checkup. He had no symptoms, although he had a medical history
of arterial hypertension and type 2 diabetes mellitus that was con-
trolled by an oral hypoglycemic agent for several years. He had
no history of alcohol addiction and had never received a blood
transfusion.
His preoperative laboratory data were as follows: platelet
count, 193 × 103/L (normal, 120–330 × 103/L); albumin,
3.3 g/dL (normal, 4.0–5.0 g/dL); total bilirubin, 0.3 mg/dL (nor-
mal, 0.2–1.0 mg/dL); aspartate aminotransferase, 53 IU/L (normal,
11–28 IU/L); alanine aminotransferase, 49 IU/L (normal, 6–30 IU/L);
blood urea nitrogen, 24.2 mg/dL (normal, 8.0–21.0 mg/dL); creat-
inine, 1.60 mg/dL (normal, 0.63–1.05 mg/dL); prothrombin time
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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big. 1. (A, B) Abdominal computed tomography revealed a hypervascular tumor wi
C)  The tumor showed no gadolinium ethoxybenzyl diethylenetriaminepentaacet
agnetic resonance imaging.
nternational normalized ratio, 0.98; and indocyanine green reten-
ion rate at 15 min, 6.6%. High serum levels of blood urea nitrogen
nd creatinine were evident, but urinary output was preserved and
erum potassium level was not elevated. In addition, proteinuria
2.5 g/day) and hypoalbuminemia were observed. Judging from his
edical history, diabetic nephropathy was thought to be respon-
ible for these abnormal ﬁndings, although a renal biopsy for
eﬁnitive diagnosis was not performed. Moreover, the elevation of
he tumor markers such as serum alpha-fetoprotein (88.0 ng/mL;
ormal, 0.0–10.0 ng/mL) and des-gamma-carboxy prothrombin
76 mAU/mL; normal, 0.0–39.9 mAU/mL) was detected; however,
est results for serum hepatitis B virus surface antigen, hepatitis
 virus core antibodies, and hepatitis C virus antibodies were
egative.
Abdominal computed tomography (CT) revealed a 3 × 2 cm2
ypervascular tumor with washout of contrast-medium located
n the right posterior section of the liver (Fig. 1A and B).
he tumor showed no gadolinium ethoxybenzyl diethylenetri-
minepentaacetic acid (Gd-EOB-DTPA) uptake and demonstrated
ypointensity on hepatocyte-phase images obtained by Gd-
OB-DTPA magnetic resonance imaging (Fig. 1C). Subsequently,
ubsegmentectomy (segment VI) of the liver and cholecystectomy
ere performed for the diagnosis of HCC.
The resected solid encapsulated tumor measured 2.6 × 2.3 cm2,
nd contained a septum that was evident on macroscopic exami-
ation (Fig. 2A). A histopathological examination of the resected
ig. 2. (A) A resected solid encapsulated tumor is macroscopically evident. (B) Tumor c
ranulomas with a tendency to coalesce scattered in the carcinoma (arrow; H&E, ×4). (
agniﬁcation (H&E, ×40). (D) Small non-necrotizing granulomas were also observed in th
ackground liver were observed at a higher magniﬁcation (H&E, ×40). (F) A slight degreehout of contrast-medium. A mass located in the right posterior section of the liver.
 (Gd-EOB-DTPA) uptake on hepatocyte-phase images obtained by Gd-EOB-DTPA
specimen revealed tumor cells that resembled hepatocytes and
grew in cords of variable thicknesses with bile plugs. Small non-
necrotizing granulomas with a tendency to coalesce were scattered
in (Fig. 2B and C) and around (Fig. 2D and E) the carcinoma. No
evidence of liver cirrhosis was found, but a slight degree of ﬁbro-
sis was  observed around the portal areas (Fig. 2F). In addition,
vascular invasion and intrahepatic metastases were not apparent,
and no features of steatohepatitis or any other liver diseases were
observed. On the basis of these ﬁndings, a ﬁnal diagnosis of HCC
associated with sarcoidosis was  conﬁrmed.
We performed several additional examinations to arrive at
a deﬁnitive postoperative diagnosis. Bilateral hilar lymphadeno-
pathy with uptake of 18F-ﬂuorodeoxyglucose was observed on
positron emission tomography/CT (Fig. 3) and the results of
tuberculin reaction test were negative. These ﬁndings conﬁrmed
systemic sarcoidosis. The patient remained healthy with no recurr-
ences or metastases at 1 year after resection.
3. Discussion
The diagnosis of hepatic sarcoidosis is difﬁcult, because liver
dysfunction is usually mild and the condition is clinically silent in
most cases.5,6 Cirrhosis or portal hypertension has been reported
in ≤1% of all sarcoidosis cases.7 In other reports, 13% fo the
patients with hepatic sarcoidosis exhibit liver involvement with-
out lung disease and approximately 35–40% have abnormal liver
ells grown in cords of variable thicknesses with bile plugs. Small non-necrotizing
C) Small non-necrotizing granulomas in the carcinoma were observed at a higher
e background liver (arrow; H&E, ×4). (E) Small non-necrotizing granulomas in the
 of ﬁbrosis can be seen around the portal areas (Azan stain, ×4).
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Table 1
Reported cases of hepatocellular carcinoma associated with sarcoidosis.
Case Year Author Age (yr)/sex Tumor size (cm) Liver cirrhosis Other complications Treatment Outcome
1 1978 Yasuda et al.16 65/M NA Present A-V block – Dead
2  1983 Kronborg et al.17 40/M NA Present – Resection Dead, 10 months
3  1999 Wong et al.18 63/M NA Absent esophageal varices BSC Dead, 5 months
4  2005 Chalasani et al.19 42/F NA Present – Chemotherapy Dead, 2 years
5  2010 Ogata et al.20 57/M 3.2 Present nephrotic syndrome Resection Alive, 2 years
6  2013 Our case 75/M 2.6 Absent proteinuria Resection Alive, 1 years
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t,  male; F, female; NA, data not available; BSC, best supportive care.
unction test results, which are most commonly indicated by
lkaline phosphatase levels.9,10 Less frequently, multiple, tiny,
ow-density nodules are detected on abdominal CT and liver
nlargement is observed in approximately 50% of patients with
odular hepatosplenic sarcoidosis.11
The relationship between sarcoidosis and carcinogenesis has not
een fully elucidated. However, the lymph nodes and lungs are
ost commonly involved, followed by the liver, and hepatic sar-
oidosis rarely causes severe complications such as jaundice, liver
ailure, cirrhosis, or portal hypertension. In addition, the association
f hepatic sarcoidosis with HCC is thought to be considerably rare.
irrhosis is an obvious risk factor for the development of HCC, but
he mechanisms by which cirrhosis predisposes to carcinogenesis
re poorly understood. Numerous studies have shown that chronic
nﬂammation and oxidative stress increase the risk of carcinogene-
is, and several recent studies have demonstrated that oxidative
tress can enhance the malignant potential of HCC through tel-
merase activation.12 Chronic inﬂammation and oxidative stress
ecause of sarcoidosis may  be associated with an increased risk of
he development of HCC. Our patient suffered from type 2 diabetes
ellitus which is reportedly a potential risk factor for HCC13,14;
herefore, additive or synergistic adverse effects to the liver because
f both sarcoidosis and diabetes mellitus may  promote the devel-
pment of HCC. Previous studies have demonstrated an increased
isk of HCC in patients with sarcoidosis; however, this result is
ig. 3. Swelling of the bilateral lung hilar lymph nodes with uptake of
8F-ﬂuorodeoxyglucose observed on positron emission tomography/computed
omography.thought to be controversial because there was no mention of hep-
atitis B or C infection, alcohol addiction, or autoimmune status of
the patients.15 On the other hand, a direct causal link between HCC
and sarcoidosis was not detected by reviewing this case. Although
the coincidence of these two diseases may  be possible, this poten-
tial comorbidity cannot be predicted by case series.
By reviewing previous cases, we found only ﬁve (four males and
one female) that described patients diagnosed with HCC associ-
ated with sarcoidosis (Table 1).16–20 The mean age of the patients,
including our patient, was 57.0 ± 12.5 years. Four patients (66.6%)
had liver cirrhosis. Case 1 presented with incidental manifestation
of sarcoidosis and HCC-associated liver cirrhosis, which terminated
in a rupture into the peritoneal cavity. Cardiac involvement was
considered as a cause of complete A-V block before death in this
patient. Case 2 also developed tumor rupture, and cases 3 and 4
were inoperable because of large tumor size. Each of these patients
died within 2 years after diagnosis. In contrast, radical hepatec-
tomy was  performed at an earlier stage of disease in case 5 and
our patient, and both of these patients have remained healthy with
no recurrences or metastases at the latest follow-up visit. These
ﬁndings suggest that the outcomes of patients with HCC associ-
ated with sarcoidosis can be improved if surgery is performed at an
earlier stage of disease.
4. Conclusion
Periodic checkups of the liver should be conducted in patients
with systemic sarcoidosis, regardless of the presence of liver cir-
rhosis.
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